In contrast, a comprehensive meta-analysis of 42 RCTs with 29,491 patients on SGLT2 inhibitors and 23,052 in control groups revealed no significant association with osteomyelitis and PAD, but a heightened risk of ulcers (Nani et al., 2023). Here, SLC5A2 is linked to osteomyelitis.